AusperBio完成5000万美元B+轮融资，推进慢性乙型肝炎功能性治愈研究-动脉网

AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B

CISION 等信源发布 2025-05-29 00:19



可切换为仅中文







SAN FRANCISCO

旧金山

，

May 28, 2025

2025年5月28日

/PRNewswire/ --

AusperBio Therapeutics, Inc

奥斯珀生物治疗公司

. and

. 和

Ausper Biopharma Co., Ltd

奥斯珀生物制药有限公司

. (collectively

。（统称为

AusperBio

奥斯珀生物

), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (

），这是一家私人持有的临床阶段生物技术公司，致力于推进靶向寡核苷酸疗法，以实现对慢性乙型肝炎的功能性治愈（

CHB

慢性乙型肝炎

), today announced the completion of an oversubscribed USD

），今天宣布已完成超额认购的美元

$50 million

5000万美元

Series B+ financing round, led by an existing, industry-leading VC investor, with strong participation from

B+轮融资，由现有行业领先的VC投资者领投，得到了强烈的参与。

Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital,

启明创投、鼎晖投资、创世资本、元生创投、汉康资本，

and

和

Sherpa Capital.

舍尔帕资本。

继续阅读

This financing follows AusperBio's Series B round completed in

本轮融资是继澳斯珀生物完成B轮融资后进行的

December 2024

2024年12月

and reflects continued investor confidence in the company's lead product, proprietary platform, and strategic direction. The proceeds will support the ongoing clinical development of

并且反映了投资者对公司主导产品、专有平台和战略方向的持续信心。所得款项将支持正在进行的临床开发工作

AHB-137

, a novel unconjugated antisense oligonucleotide for chronic hepatitis B (

，一种用于慢性乙型肝炎的新型非结合型反义寡核苷酸（

CHB

慢性乙型肝炎

), including planned Phase II trials outside of mainland

），包括计划在大陆以外进行的二期试验

China

中国

. The funding will also enable scale-up of commercial manufacturing partnerships and support the company's long-term pipeline growth.

这笔资金还将扩大商业制造合作伙伴关系的规模，并支持公司的长期管道增长。

AusperBio, CHB, ASO, Functional Cure, Financing, Series B+

奥斯珀生物，慢性乙型肝炎，反义寡核苷酸，功能性治愈，融资，B+轮

Post this

发布这个

Dr.

博士

Guofeng Cheng

国风城

, co-founder and CEO of AusperBio, commented,

AusperBio的联合创始人兼首席执行官评论道，

'We are greatly honored by the continued support from our investors. It's a strong vote of confidence in our vision and the progress we've made so far. This new funding gives us the momentum to move AHB-137 into the next phase of global development. We are committed to stay focused on our mission to deliver a functional cure for chronic hepatitis B and bring life-changing therapies to patients worldwide.'.

“我们非常荣幸能够继续得到投资者的支持。这是对我们愿景以及迄今为止所取得进展的强烈信任投票。这笔新的资金为我们提供了动力，将AHB-137推进到全球开发的下一阶段。我们致力于专注于实现为慢性乙型肝炎提供功能性治愈，并为全球患者带来改变生命的疗法的使命。”

Dr.

博士

Chris Yang

杨克里斯

, co-founder and CSO, added, '

`, 联合创始人兼首席战略官（CSO）补充道，'`

We are strongly encouraged by the recent progress of AHB-137, particularly the positive Phase IIb data presented at the EASL Congress in

我们对AHB-137的近期进展感到非常鼓舞，特别是在EASL大会上展示的积极的IIb期数据。

Amsterdam

阿姆斯特丹

. With strong investor support, the AusperBio team is fully motivated to continue our clinical strategies and efforts to bring new treatment options to people living with CHB.

在投资者的大力支持下，AusperBio团队全力推进我们的临床策略和努力，为慢性乙型肝炎患者带来新的治疗选择。

AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms for this serious chronic disease.

AusperBio致力于提供以患者为中心的创新，旨在减轻CHB的全球健康负担，并改变这种严重慢性疾病的治疗模式。

About AHB-137

关于 AHB-137

AHB-137, a novel unconjugated antisense oligonucleotide (

AHB-137，一种新型未结合的反义寡核苷酸（

ASO

应用商店优化

) designed using AusperBio's proprietary

) 采用 AusperBio 专有技术设计

Med-Oligo™ ASO

technology platform, is being developed to achieve a functional cure for chronic hepatitis B. Its clinical development has generated compelling data, with key preclinical and clinical results presented at leading conferences such as EASL (2023, 2024, 2025) and AASLD (2024). This novel dual-mechanism ASO has completed its global Phase .

技术平台，旨在实现对慢性乙型肝炎的功能性治愈。其临床开发已产生了令人信服的数据，关键的临床前和临床结果已在EASL（2023、2024、2025年）和AASLD（2024年）等顶级会议上展示。这种新型双机制反义寡核苷酸（ASO）已完成其全球二期临床试验。

trial and is currently advancing through multiple Phase 2 studies in

试验，并且目前正在进行多个二期研究

China

中国

. Supported by a clear global development strategy, AHB-137 is progressing rapidly toward delivering a potential cure for HBV.

在明确的全球发展战略支持下，AHB-137 正在快速推进，有望为乙型肝炎提供治愈方案。

About AusperBio.

关于AusperBio。

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and

AusperBio 是一家临床阶段的生物制药公司，业务遍及美国和

China

中国

, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary

，致力于推进寡核苷酸和靶向递送技术以实现变革性治疗，最初专注于实现慢性乙型肝炎感染的功能性治愈。该公司已经开发了一种专有的

Med-Oligo

寡聚物医疗

™

ASO

应用商店优化

platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular

该平台通过全新的ASO设计见解，显著提升了当前的ASO治疗效果。结合高效的靶向递送结合技术，这一模块化

Med-Oligo™

Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

平台助力ASO疗法治疗多种疾病，包括病毒感染、代谢疾病、遗传病和免疫疾病。

For further information, please contact:

如需更多信息，请联系：

Media Contact

媒体联系人

Email:

电子邮件：

info@ausperbio.com

Investor Relations Contact:

投资者关系联系人：

Tel: 650-888-1756 (US)

电话：650-888-1756（美国）